Regenerative medicine company Orthocell Limited is pleased to announce positive 3-5 year data from a study of its tendon cell treatment for tennis elbow has been presented at the International Cartilage Repair Society annual scientific meeting.
The data shows Orthocell’s Ortho-ATITM therapy significantly improved the clinical outcome of patients with long term tennis elbow degeneration, showing reduced pain and increased functionality out to five years.
The International Cartilage Repair Society is a leading international conference of musculoskeletal experts and Orthocell presented at its annual scientific meeting held in Chicago, USA. Orthocell’s Chief Scientific Officer, Professor Ming Hao Zheng, from the University of Western Australia’s School of Surgery and Centre for Orthopaedic Research, presented the study.
Orthocell Managing Director, Mr Paul Anderson, said:
Health professionals around the world are becoming more aware of Ortho-ATITM and its long-term effectiveness in treating musculoskeletal conditions such as tennis elbow and other problematic tendons. Acceptance of this data at international meetings of this standard is further validation of the relevance of this exciting new approach to this difficult clinical challenge.
He said Orthocell and its world-leading stem cell regeneration therapies are providing significant relief to patients.
As the population ages, mobility becomes a significant issue and degenerate tendon conditions become more prevalent, so doctors and patients are seeking out proven treatments to increase patients’ mobility and quality of life.
The pilot study investigated the effect of Ortho-ATITM in 17 patients who were all assessed by an independent therapist out to five years, representing one of the longest data sets in cell therapies today.
Patients demonstrated an incredible 207% increase in their grip strength abilities and were ‘highly satisfied’ with the outcome of their treatment.
Transparency Market Research estimate that the US, Europe and Japan markets for tennis elbow treatment is estimated to be worth US$700 million in 2015.